Collecting blood and urine samples from bladder cancer patients
Bladder Bank (a Prospective Banking Study)
This study is collecting blood and urine samples from bladder cancer patients to see if these samples can help create better tests for early detection of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT06109857 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a biobank of blood and urine samples from patients diagnosed with bladder carcinoma. The primary objective is to support the development of non-invasive tests for the early detection of bladder cancer. Participants will undergo sample collection and have their medical records reviewed while enrolled in the study. This approach allows researchers to gather valuable biological materials that can aid in advancing diagnostic methods for bladder cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years who have undergone evaluation for hematuria.
Not a fit: Patients with known cancer outside of bladder carcinoma or those with recurrent muscle invasive bladder cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection methods for bladder cancer, potentially increasing survival rates.
How similar studies have performed: Other studies have successfully established biobanks for cancer research, indicating that this approach has potential for meaningful contributions to early detection methods.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Patient has undergone office-based evaluation for hematuria \[computed tomography (CT), ultrasound, cystoscopy\] Exclusion Criteria: * Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible) * Patient has recurrent muscle invasive bladder cancer * Patient has ever been previously diagnosed with UTUC (upper tract urothelial carcinoma) prior to bladder resection * Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection * Patient has had any prior radiation therapy to the target lesion prior to current collection * Patient has had a biopsy to the target organ and/or lesion within 3 days before collection * Patient has undergone cystectomy or cystoprostatectomy * Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection * Patient has had a urinary tract infection within 14 days prior to urine collection * Patient has chronic indwelling urinary catheter
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: John B. Kisiel, MD — Mayo Clinic in Rochester
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.